Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Long-Term Debt Repayments: 2009-2018

Historic Long-Term Debt Repayments for Gyre Therapeutics (GYRE) over the last 8 years, with Mar 2018 value amounting to $5.1 million.

  • Gyre Therapeutics' Long-Term Debt Repayments fell 24.73% to $5.1 million in Q1 2018 from the same period last year, while for Mar 2018 it was $12.6 million, marking a year-over-year decrease of 30.83%. This contributed to the annual value of $5.1 million for FY2018, which is 64.51% down from last year.
  • As of Q1 2018, Gyre Therapeutics' Long-Term Debt Repayments stood at $5.1 million, which was up 1,161.04% from $403,000 recorded in Q4 2017.
  • In the past 5 years, Gyre Therapeutics' Long-Term Debt Repayments ranged from a high of $10.3 million in Q4 2016 and a low of $218,000 during Q1 2014.
  • Over the past 3 years, Gyre Therapeutics' median Long-Term Debt Repayments value was $2.8 million (recorded in 2016), while the average stood at $3.7 million.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first spiked by 1,089.46% in 2016, then slumped by 96.07% in 2017.
  • Gyre Therapeutics' Long-Term Debt Repayments (Quarterly) stood at $478,000 in 2014, then skyrocketed by 80.54% to $863,000 in 2015, then soared by 1,089.46% to $10.3 million in 2016, then crashed by 96.07% to $403,000 in 2017, then decreased by 24.73% to $5.1 million in 2018.
  • Its Long-Term Debt Repayments stands at $5.1 million for Q1 2018, versus $403,000 for Q4 2017 and $282,000 for Q3 2017.